Artificial Intelligence
Global Gene Therapy Market Report 2020: Market is Expected to Recover and Reach $6.84 Billion in 2023 – Forecast to 2030
![](https://roboticulized.com/wp-content/uploads/2020/12/global-gene-therapy-market-report-2020-market-is-expected-to-recover-and-reach-6-84-billion-in-2023-forecast-to-2030.jpg)
Dublin, Dec. 08, 2020 (GLOBE NEWSWIRE) — The “Gene Therapy Global Market Report 2020-30: COVID-19 Growth and Change” report has been added to ResearchAndMarkets.com’s offering.
Gene Therapy Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global gene therapy market market.
Major players in the gene therapy market are Novartis AG, Bluebird Bio, Inc., Spark Therapeutics, Inc., Audentes Therapeutics, Voyager Therapeutics, Applied Genetic Technologies Corporation, UniQure N.V., Celgene Corporation, Cellectis S.A. and Sangamo Therapeutics.
The global gene therapy market is expected to decline from $3.22 billion in 2019 to $3.18 billion in 2020 at a compound annual growth rate (CAGR) of -1.30%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The market is then expected to recover and reach $6.84 billion in 2023 at a CAGR of 29.09%.
The gene therapy market consists of sales of gene therapy related services by entities (organizations, sole traders and partnerships) that manufacture gene therapy drugs. Gene therapy is used to replace faulty genes or add new genes to cure disease or improve the body’s ability to fight disease. Only goods and services traded between entities or sold to end consumers are included. North America was the largest region in the gene therapy market in 2019.
The gene therapy market covered in this report is segmented by gene type into antigen; cytokine; suicide gene; others. It is also segmented by vector into viral vector; non-viral vector; others, by application into oncological disorders; rare diseases; cardiovascular diseases; neurological disorders; infectious diseases; others, and by end users into hospitals; homecare; specialty clinics; others.
In December 2019, Roche, a Switzerland-based company, completed its acquisition of Spark Therapeutics for $4.3 billion. With this deal, Roche is expected to strengthen its presence in the gene therapy segment, support transformational therapies and increase its product portfolio. Spark Therapeutics is a US-based company involved in gene therapy.
The high prices of gene therapy medicines are expected to limit the growth of the gene therapy market. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, the lack of cost-effective therapies for cancer and other diseases has influenced the health conditions of the population and has led to a low average life expectancy.
Luxturna, a one-time treatment for acquired retinal eye disease, costs $850,000 in the US and 613,410 in the UK, despite a markdown that is applied through Britain’s National Health Service. Zolgensma, for spinal muscular atrophy, is valued at $2.1 million in the US and Zynteglo, which focuses on a rare genetic blood disorder, costs $1.78 million, thus restraining the growth of the market. The use of machine learning and artificial intelligence is gradually gaining popularity in the gene therapy market. Artificial intelligence (AI) is the simulation of human intelligence in machines, which are programmed to display their natural intelligence. Machine learning is a part of AI.
Machine learning and AI help companies in the gene therapy market to conduct a detailed analysis of all relevant data, provide insights between tumor and immune cell interactions, and offer a more accurate evaluation of tissue samples often conflicted between different evaluators. For instance, since January 2020, GlaxoSmithKline, a pharmaceutical company, has been investing in AI to optimize gene therapy and develop off-the-shelf solutions for patients. It is also expected to reduce turnaround time and also the cost of gene therapies.
Key Topics Covered:
1. Executive Summary
2. Gene Therapy Market Characteristics 3. Gene Therapy Market Size And Growth 4. Gene Therapy Market Segmentation 4.2. Global Gene Therapy Market, Segmentation By Vector, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
4.3. Global Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
4.4. Global Gene Therapy Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5. Gene Therapy Market Regional And Country Analysis Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/r/y5rj2q
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
3.1. Global Gene Therapy Historic Market, 2015 – 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Gene Therapy Forecast Market, 2019 – 2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market
4.1. Global Gene Therapy Market, Segmentation By Gene Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.1. Global Gene Therapy Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Gene Therapy Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Artificial Intelligence
Scorpios’ Summer Cultural Series Redefines AI & Visual Art in Mykonos & Bodrum
![scorpios’-summer-cultural-series-redefines-ai-&-visual-art-in-mykonos-&-bodrum](https://roboticulized.com/wp-content/uploads/2024/07/150975-scorpios-summer-cultural-series-redefines-ai-visual-art-in-mykonos-bodrum.jpg)
LONDON, July 3, 2024 /PRNewswire/ — Scorpios, the renowned beach concept and creative gathering place, in partnership with art tech pioneers HOFA Gallery, announces ‘Evolving Perspectives’ the second edition of their Encounters summer arts programme. Running from 18 July to 18 September, this 9-week series expands to take place across Scorpios’ two stunning beachfront locations, Mykonos and the newly opened Bodrum. Featuring immersive installations and live music performances, the programme will showcase AI and visual artists, headlined by Joseph Klibansky, Random International, and Sougwen Chung – all revered for pushing the boundaries of art and technology.
Building on the success of 2023’s inaugural edition launched with Turkish AI artist and director Refik Anadol, his special collaboration with the Yawanawa Indigenous communities of Brazil’s Amazon, was regarded as a profound exploration of the relationship between human consciousness and nature. Over half a million people attended last year’s programme, generating $3 million in artwork sales, with Refik Anadol’s Yawanawa heritage project alone selling out in hours and raising $1.5 million for the preservation campaign.
HOFA Co-founder Elio D’Anna says: “The 2023 season of Encounters was a groundbreaking and very successful programme that brought together AI and digital artists, musicians, and an audience of global changemakers and creatives through a series of live performances and installations.
“This year’s ‘Evolving Perspectives’ programme continues to push boundaries, making it the most exciting synchronisation of visual art and cultural engagement, while also delivering a very powerful message on the power of AI and human-machine collaboration to help us achieve a more harmonious coexistence with nature.”
The Mykonos lineup headlines Dutch contemporary artist Joseph Klibansky from 18-21 July 2024. Celebrated for his innovative use of technology in art and sculpture, will present ‘Tree of Life’ merging digital art with environmental stewardship. This collection creates a unified visual narrative rich in depth and storytelling, featuring intricate patterns and vibrant colours inspired by nature. The new ‘Tree of Life’ collection includes a large-scale video sculpture installation to be exhibited at Scorpios Mykonos, along with 1,000 unique digitally painted fine art prints with a matching digital companion. Each artwork boasts its own unique traits, ensuring every piece is one-of-a-kind.
Moreover, Klibansky combines visual art with environmental awareness. For every artwork sold, the partnering non-profit One Tree Planted will plant physical trees in the Amazon.
In Bodrum between 22-25 August 2024, the art group Random International, a German duo with studios in London and Stockholm, will present an immersive installation that invites visitors to engage physically with a seemingly sentient, digital swarm. Titled ‘When Tomorrow Comes’, the work features a custom tracking system and flocking algorithm to create an interactive digital sculpture blending technology with human perception and interaction. 3 sets of 150 limited signed edition prints of ‘When Tomorrow Comes’ will be available for purchase.
A global name in human-machine collaboration, and multi-award winning Chinese-Canadian artist Sougwen 愫君 Chung will perform a live showcase with the robotic system D.O.U.G. (Drawing Operations Unit Generation at Scorpios Bodrum between 5-8 September 2024. The single scheduled performance during that weekend offers a unique opportunity to experience their groundbreaking collaborative work. Chung’s innovative approach to combining human artistry with AI technology has earned them international acclaim, including a spot on TIME Magazine’s TIME100 AI list as one of the world’s most influential people in AI and the TIME Impact Award 2024.
Accompanying the performance will be the debut of ‘Genesis II: Body Machine’, a collection of unique artworks. The works in ‘Body Machine’ speculate on the future of the robotic form intertwined with the human body. Each bespoke work is generated from the artist’s drawing choreography captured in three dimensions and paired with exclusive signed prints.
All prints and digital artworks will be available for purchase through Scorpios Collect.
The headline artist events are also supported by a programme of featured AI and visual artists, encompassing music into these collaborative events, they will take place throughout the 2024 summer season in both Mykonos and Bodrum.
Scorpios Co-Founder Thomas Heyne says: “We use digital art to create holistic experiences. Interaction and immersion enhance the overall experience, taking guests on a journey where they feel inspired. We are excited to welcome Joseph Klibansky, Random International, and Sougwen Chung to this year’s Encounters program, showcasing how AI can teach us about living in harmony with nature.”
WWW.THEHOUSEOFFINEART.COMWWW.SCORPIOS.COMWWW.SCORPIOS.COM/ENCOUNTERSWWW.SCORPIOSCOLLECT.COM
Media contact: Emma-Louise O’Neill; [email protected]; +44 7515 136909
Photo – https://mma.prnewswire.com/media/2452902/Tree_of_Life_Joesph_Klibanksy_HOFA_Gallery.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/scorpios-summer-cultural-series-redefines-ai–visual-art-in-mykonos–bodrum-302188305.html
Artificial Intelligence
Two Belgian hospitals live with Sectra’s public cloud service for medical imaging based on Microsoft Azure
![two-belgian-hospitals-live-with-sectra’s-public-cloud-service-for-medical-imaging-based-on-microsoft-azure](https://roboticulized.com/wp-content/uploads/2024/07/150977-two-belgian-hospitals-live-with-sectras-public-cloud-service-for-medical-imaging-based-on-microsoft-azure.png)
LINKÖPING, Sweden, July 3, 2024 /PRNewswire/ — Two hospitals in Belgium are successfully live with the public cloud service from international medical imaging IT and cybersecurity company Sectra (STOCKHOLM: SECT-B). As the first to use Sectra One Cloud in the Benelux countries, the two hospitals have begun experiencing the benefits of a cloud service such as improved ability to share resources between the sites and more streamlined workflows.
In the city of Bruges in Belgium, the hospitals AZ Sint Lucas and AZ Sint Jan began their journey to the cloud following a contract with Sectra signed in 2023. As the first in the Benelux countries to adopt Sectra’s enterprise imaging as a fully managed service in the public cloud, these hospitals have now gone live with the service.
One of the main reasons for this shift was the need to streamline operations and enhance collaboration between the two sites. Since 2021, the 23 radiologists and nine trainees of both hospitals have worked together in one single association. Previously, they were unable to work in one environment as they were using two different PACS providers. This made it much harder to collaborate. This need originates from the challenge many hospitals face today of dealing with heavy workloads.
“With an aging population come increasing needs. We are already experiencing a lack of resources and heavier workload. With more and more exams to report on and a shortage of staff, our radiologists are having a hard time coping with the everyday workload. A state-of-the art communal PACS system could help streamline workflow and improve efficiency,” says Dr. Jesse Marrannes, radiologist at AZ Sint-Jan and main medical responsible for this PACS project.
Bart Thielen, Managing Director, Sectra Benelux, adds: “Healthcare today needs to be able to cope with the increasing need for diagnostics and specialized care. Transitioning to the cloud is the first step for hospitals wanting to use new technology to cope with these challenges, as the service offers the needed scalability and security. Many hospitals also deal with staff shortages when it comes to qualified IT staff. I am very happy to offer a solution that will take away some of the stress and resources usually needed to manage the system.”
He continues: “AZ Sint Jan and AZ Sint Lucas pave the way for the transition to public cloud for medical imaging in the Benelux and I’m excited to follow their journey.”
The service is based on Microsoft Azure and fully managed by Sectra. The hospitals saw the potential of the service helping to relieve burden on their IT staff and resources. “The fact that it is a fully managed service and deployed in the cloud gives us more time to focus on the care of our patients rather than on the maintenance of the IT-system and the storage and accessibility of data,” said Annelies Meyns, Head of ICT Applications at AZ Sint Jan, when the project was initiated.
The implementation process began shortly after the contract was signed, with Sectra closely collaborating with hospital teams to ensure a seamless transition. “Moving everything to the cloud is a monumental task, but Sectra’s commitment made it manageable and efficient,” says Jurryt Laleeuwe, Head of ICT Applications at AZ Sint Lucas.
The cloud service is now fully operational, bringing notable enhancements. “The new system has already enhanced our ability to share resources and collaborate on patient cases. The ability to tailor our workflows has also greatly benefited our radiologists, especially for overarching multidisciplinary team meetings” says Dr. Pieter Vandaele, Head of the Department of Radiology at AZ Sint Lucas.
He continues: “The implementation and experience so far have been very positive, and I look forward to seeing the ongoing benefits of this cloud service.”
Sectra’s enterprise imaging solution provides a unified strategy for all imaging needs while lowering operational costs. The scalable and modular solution, with a VNA at its core, allows healthcare providers to grow from ology to ology and from enterprise to enterprise. Visit Sectra’s website to read more about Sectra and why it’s top-ranked in “Best in KLAS.”
About SectraSectra contributes to a healthier and safer society by assisting health systems throughout the world to enhance the efficiency of care, and authorities and defense forces in Europe to protect society’s most sensitive information. The company, founded in 1978, is headquartered in Linköping, Sweden, with direct sales in 19 countries, and distribution partners worldwide. Sales in the 2023/2024 fiscal year totaled SEK 2,964 million. The Sectra share is quoted on the Nasdaq Stockholm exchange. For more information, visit Sectra’s website.
For further information, please contact:Dr. Torbjörn Kronander, CEO and President Sectra AB, 46 (0) 705 23 52 27 Marie Ekström Trägårdh, Executive Vice President Sectra AB and President Sectra Imaging IT Solutions, 46 (0)708 23 56 10
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/sectra/r/two-belgian-hospitals-live-with-sectra-s-public-cloud-service-for-medical-imaging-based-on-microsoft,c4007517
The following files are available for download:
https://news.cision.com/sectra/i/sectra-s-module-for-breast-imaging,c3315483
Sectra’s module for breast imaging
View original content:https://www.prnewswire.co.uk/news-releases/two-belgian-hospitals-live-with-sectras-public-cloud-service-for-medical-imaging-based-on-microsoft-azure-302188707.html
Artificial Intelligence
Barrington James Announces Strategic Acquisition of S3 Science Recruitment
![barrington-james-announces-strategic-acquisition-of-s3-science-recruitment](https://roboticulized.com/wp-content/uploads/2024/07/150979-barrington-james-announces-strategic-acquisition-of-s3-science-recruitment.jpg)
LONDON, July 3, 2024 /PRNewswire/ — Barrington James, a global leader in Life Science Recruitment, proudly announces the acquisition of S3 Science Recruitment, a firm renowned for its expertise in drug discovery, medical research, and the broader field of life sciences. Terms of the transaction were not disclosed.
This strategic acquisition marks a significant milestone for Barrington James, enhancing the company’s commitment to expanding its client-service capabilities and supporting the development of cutting-edge technology. This integration will provide clients with greater access to exceptional talent on both a permanent and temporary basis.
Dan Barrington, CEO of Barrington James, stated: “We are thrilled to acquire S3 and expand our Human Capital services in Life Sciences. This acquisition enhances our offerings across Board and Executive partnerships, Permanent Recruitment, Contract Recruitment, Staffing, OSP, and FSP. S3’s expertise in Clinical and Pre-Clinical specializations, both on a temporary and permanent basis, will perfectly complement Barrington James’ comprehensive Life Science services, from Clinical to Post-Marketing, A.I., and beyond. We are excited to collaborate with Alex Barrie, and his team, and we look forward to significantly growing S3 in the coming years.”
Alex Barrie, Director of Recruitment at S3, stated: “Clients of S3 Science Recruitment can expect a seamless transition, marked by the same dedication to excellence and personalized service they have come to rely on. Like Barrington James, we are deeply committed to delivering exceptional value and support to all our clients. By integrating the strengths of both companies, we are not only maintaining our high standards but also elevating them. The exciting integration of S3 Science into Barrington James enables us to offer an even broader and more comprehensive range of staffing solutions, ensuring that our clients benefit from a superior recruitment experience.”
About Barrington James:
Barrington James is a global, industry-leading recruitment business serving the Pharmaceutical, Biotechnology, and Medical Device sectors. With a global presence and a team of hundreds of specialists, we deliver world-class recruitment solutions to life science companies of all sizes. Leveraging a network of over 6 million industry professionals and advanced AI platforms, our expert consultants provide a personalized approach to global life science recruitment. For more information, please visit barringtonjames.com.
About S3 Science Recruitment:
S3 Science Recruitment connects talented individuals with leading organizations and institutions across the UK, Europe, and the United States. Our mission is to enable groundbreaking discoveries and life-saving treatments today. Specializing in drug discovery, medical research, and the broader Life Sciences field, we support the UK’s leadership in developing cures and treatments. Since 2002, S3 Science Recruitment has helped Life Sciences organizations find passionate individuals dedicated to medical advancement, particularly in animal research. We believe attracting talent to this vital industry is just the beginning of greater achievements. For more information, please visit s3science.com.
CONTACT: Amy TilburyHead of [email protected]+44 (0) 1293 776644
Photo – https://mma.prnewswire.com/media/2452929/Barringtonjames.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/barrington-james-announces-strategic-acquisition-of-s3-science-recruitment-302188155.html
-
Artificial Intelligence5 days ago
Spotlight on Authentic AI: Developers Making Real Contributions Beyond AI Washing Claims
-
Artificial Intelligence5 days ago
CO2 AI Launches First Solution to Compute Product Emissions at Scale
-
Artificial Intelligence5 days ago
Asia Pacific View: Foreigners Looking for the Most Practical Smart Technology at the 2024 World Intelligence Expo
-
Artificial Intelligence4 days ago
Lucinity’s AI Innovation Recognized at Microsoft’s Prestigious Global Partner Awards 2024
-
Artificial Intelligence5 days ago
Tech Companies Leading the Charge in the Transformative AI Era
-
Artificial Intelligence5 days ago
North American grocery retailer digitizes stores with Pricer Plaza in 90 MSEK order
-
Artificial Intelligence5 days ago
Hybrid Memory Cube Market Size to Grow USD 18651.2 Million by 2030 at a CAGR of 18.6% | Valuates Reports
-
Artificial Intelligence5 days ago
Learning Pool Recognized with Two Industry Awards for Innovation and Product Excellence